Emergencies Related to Cancer Chemotherapy and Hematopoietic Stem Cell Transplantation

Emergency Medicine Clinics of North America

Volumn 27, Issue 2, 2009, Pages 311-331

  Adelberg, David E ^a   Bishop, Michael R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anemia; Cardiotoxicity; Chemotherapy; Graft versus host disease; Neutropenia; Stem cell transplant

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; ATROPINE PLUS DIPHENOXYLATE; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; LOPERAMIDE; ONDANSETRON; OXALIPLATIN; STREPTOZOCIN; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

ANEMIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DRUG HYPERSENSITIVITY; EMERGENCY CARE; FATIGUE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION COMPLICATION; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW;

EID: 65549158362     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2009.01.005     Document Type: Review

References (106)

1. Kris M.G., Gralla R.J., Tyson L.B., et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7 1 (1989) 108-114
2. Hesketh P. Prevention and treatment chemotherapy-induced nausea and vomiting. Available at: www.uptodate.com. Accessed June 15, 2008.
3. Hesketh P. Chemotherapy-induced nausea and vomiting. N Engl J Med 358 (2008) 2482-2494
4. Halmos B, Krishnamurthi S. Enterotoxicity of chemotherapeutic agents. Available at: www.uptodate.com. Accessed June 15, 2008.
5. Common toxicity criteria, version 3.0, National Institutes of Health, National Cancer Institute. Available at: www.ctep.info.nih.gov. Accessed July 15, 2008.
6. Holland J.F., Scharlau C., Gailani S., et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33 (1973) 1258-1264
7. Anderson H., Scarffe J.H., Lambert M., et al. VAD chemotherapy-toxicity and efficacy-in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 5 (1987) 213-222
8. Weed H.G. Lactulose vs sorbitol for treatment of obstipation in hospice programs. Mayo Clin Proc 75 5 (2000) 541
9. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
10. Wright J.D., Hagemann A., Rader J.S., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107 (2006) 83-89
11. Robbins G. Fever in the neutropenic adult patient with cancer. Available at: www.uptodate.com. Accessed June 15, 2008.
12. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 6 (2002) 730-751
13. Schimpff S.C., Satterlee W., Young V.M., et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284 (1971) 1061-1065
14. Peacock J.E., Herrington D.A., Wade J.C., et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 137 2 (2002) 77-86
15. Bliziotis I.A., Michalopoulos A., Kasiakou S.K., et al. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 80 9 (2005) 1146-1156
16. Pizzo P.A., Hathorn J.W., Hiemenz J., et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315 9 (1986) 552-558
17. Cometta A., Calandra T., Gaya H., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrobial Agents Chemother 40 5 (1996) 1108-1115
18. Paul M., Borok S., Fraser A., et al. Additional anti-gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 3 (2005) CD003914
19. Paul M., Borok S., Fraser A., et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55 (2005) 436-444
20. Aoun M. Review: additional anti-gram-positive antibiotics do not reduce all-cause mortality in cancer and febrile neutropenia. [comment]. ACP J Club 144 (2006) 3
21. Freifeld A., Baden L., Brown A., et al. Fever and neutropenia. J Natl Compr Canc Netw 2 5 (2004) 390-432
22. Clark O., Lyman G., Castro A., et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23 18 (2005) 4198-4214
23. Santolaya M.E., Alvarez A.M., Aviles C.L., et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22 18 (2004) 3784-3789
24. Kamana M., Escalante C., Mullen C.A., et al. Bacterial infections in low-risk, febrile neutropenic patients. Cancer 104 2 (2005) 422-426
25. Stone P., Richardson A., Ream E., et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 11 8 (2000) 971-975
26. Mock V., Atkinson A., Barsevick A., et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Huntington) 14 (2000) 151-161
27. Wang X.S., Giralt S.A., Mendoza T.R., et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol 20 5 (2002) 1319-1328
28. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91 19 (1999) 1616-1634
29. Schrier S. Steensma D. Loprinzi C. Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer. Available at: www.uptodate.com. Accessed June 15, 2008.
30. Smith Jr. R.E., Aapro M.S., Ludwig H., et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26 7 (2008) 1040-1050
31. Perry M. Chemotherapy and liver disease. Available at: www.uptodate.com. Accessed June 15, 2008.
32. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11 2 (1990) 272-276
33. Maria V.A., and Victorino R.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 26 3 (1997) 664-669
34. Kawatani T., Suou T., Tajima F., et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67 1 (2001) 45-50
35. Zuckerman E., Zuckerman T., Douer D., et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 83 6 (1998) 1224-1230
36. Floyd J, Morgan J, Perry M. Cardiotoxicity of anthracycline-like chemotherapy agents. Available at: www.uptodate.com. Accessed June 15, 2008.
37. Vogelzang N.J. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Huntington) 5 (1991) 97-102
38. Ries F., and Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8 (1986) 368-379
39. Bressler R.B., and Huston D.P. Water intoxication following moderate dose intravenous cyclophosphamide. Arch Intern Med 145 (1985) 548-549
40. Merchan J. Chemotherapy and renal insufficiency. Available at: www.uptodate.com. Accessed June 15, 2008.
41. Cantrell Jr. J.E., Phillips T.M., and Schein P.S. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 3 (1985) 723-734
42. Yang H., Rosove M.H., and Figlin R.A. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 62 (1999) 247-250
43. Sandler A.B., Johnson D.H., and Herbst R.S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10 (2004) 4258S-4262S
44. Schrag D., Chung K.Y., Flombaum C., et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97 (2005) 1221-1224
45. Belldegrun A., Webb D.E., Austin III H.A., et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106 (1987) 817-822
46. Guleria A.S., Yang J.C., Topalian S.L., et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. J Clin Oncol 12 (1994) 2714-2722
47. Ault B.H., Stapleton F.B., Gaber L., et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 319 21 (1988) 1397-1400
48. Anand A.J. Fluorouracil cardiotoxicity. Ann Pharmacother 28 (1994) 374-378
49. Tolba K.A., and Deliargyris E.N. Cardiotoxicity of cancer therapy. Cancer Invest 17 (1999) 408-422
50. Telli M.L., Hunt S.A., Carlson R.W., et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25 (2007) 3525-3533
51. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007) 2011-2019
52. Vogelzang N.J., Frenning D.H., and Kennedy B.J. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 64 (1980) 1159-1160
53. Gilbert M.R. The neurotoxicity of cancer chemotherapy. Neurologist 4 (1998) 43-53
54. Keime-Guibert F., Napolitano M., and Delattre J.Y. Neurological complications of radiotherapy and chemotherapy. J Neurol 245 (1998) 695-708
55. Wen P.Y. Central nervous system complications of cancer therapy. In: Schiff D., and Wen P.Y. (Eds). Cancer neurology in clinical practice (2002), Humana Press, Totowa (NJ) 287-326
56. Lee J.J., and Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24 (2006) 1633-1642
57. Verstappen C.C., Koeppen S., Heimans J.J., et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64 (2005) 1076-1077
58. Van den Bent M.J., Hilkens P.H., Sillevis Smitt P.A., et al. Lhermitte's sign following chemotherapy with docetaxel. Neurology 50 (1998) 563-564
59. Wen P. Plotkin S. Neurologic complications of cancer chemotherapy. Available at: www.uptodate.com. Accessed July 15, 2008.
60. Phillips P.C. Methotrexate toxicity. In: Rottenberg D.A. (Ed). Neurological complications of cancer treatment (1991), Butterworth-Heinemann, Boston 115
61. Walker R.W., Allen J.C., Rosen G., et al. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 4 (1986) 1845-1850
62. Jardine L.F., Ingram L.C., and Bleyer W.A. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol 18 (1996) 302-304
63. Spiegel R.J., Cooper P.R., Blum R.H., et al. Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 311 (1984) 386-388
64. Widemann B.C., Balis F.M., Shalabi A., et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 96 (2004) 1557-1559
65. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 4 (2004) 277-284
66. Sonis S.T., Elting L.S., Keefe D., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 (2004) 1995-2025
67. Keefe D.M., Schubert M.M., Elting L.S., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109 (2007) 820-831
68. National Cancer Institute Common Toxicity Criteria, version 3.0; 2003.
69. Peterson D.E., and Schubert M.M. Oral toxicity. In: Perry M.C. (Ed). The chemotherapy source book. 3rd edition (2001), Williams & Wilkins, Baltimore (MD) 115-136
70. Toljanic J. Bedard JF, Joyce R. Oral toxicity associated with chemotherapy. Available at: www.uptodate.com. Accessed July 15, 2008.
71. Dreizen S., Bodey G.P., and Valdivieso M. Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg Oral Med Oral Pathol 55 (1983) 113-120
72. Redding S.W. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 9 (1990) 103-105
73. Coda B.A., O'Sullivan B., Donaldson G., et al. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 72 (1997) 333-346
74. Alley E., Green R., and Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14 (2002) 212-216
75. Koon H. Drews R. Hypersensitivity reactions to systemic chemotherapy. Available at: www.uptodate.com. Accessed July 15, 2008.
76. Albanell J., and Baselga J. Systemic therapy emergencies. Semin Oncol 27 (2000) 347-361
77. Rahman A., Treat J., Roh J.K., et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8 (1990) 1093-1100
78. Leung W.H., Lau J.Y., Chan T.K., et al. Fulminant hyperpyrexia induced by bleomycin. Postgrad Med J 65 764 (1989) 417-419
79. Payne A. Harris J. Savarese D. Chemotherapy extravasation injury. Available at: www.uptodate.com. Accessed July 15, 2008.
80. Fischer D., Knobf M., and Durivage H. The cancer chemotherapy handbook (1997), Mosby, St Louis (MO) p. 514
81. Goolsby T.V., and Lombardo F.A. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 33 (2006) 139-143
82. Dorr R.T., and Alberts D.S. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74 (1985) 113-120
83. Larson D.L. Treatment of tissue extravasation by antitumor agents. Cancer 49 (1982) 1796-1799
84. Susser W.S., Whitaker-Worth D.L., and Grant-Kels J.M. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40 (1999) 367-398
85. Wingard J.R. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 6 (1990) 371-383
86. Wingard J.R. Bacterial infections. In: Forman S.J., Blume K.G., and Thomas E.D. (Eds). Hematopoietic cell transplantation (1994), Blackwell Scientific, Boston 537-549
87. Wingard J.R. Infections in allogeneic bone marrow transplant recipients. Semin Oncol 20 (1993) 80-87
88. Anaissie E., Bodey G.P., Kantarjian H., et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91 (1991) 142-150
89. Abi-Said D., Anaissie E., Uzun O., et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24 (1997) 1122-1128
90. Sable C.A., and Donowitz G.R. Infections in bone marrow transplant recipients. Clin Infect Dis 18 (1994) 273-281
91. Boyiadzis M., Gea-Benacloche J., and Bishop M. Complications and follow-up after Hematopoietic Stem Cell Transplantation (HSCT). In: Boyiadzis M., Lebowitz P., Frame J., et al. (Eds). Hematology-oncology therapy (2007), McGraw-Hill, New York 674-693
92. Harrington R.D., Hooton T.M., Hackman R.C., et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 165 (1992) 987-993
93. Ljungman P., Gleaves C.A., and Meyers J.D. Respiratory virus infection in immunocompromised patients. Bone Marrow Transplant 4 (1989) 35-40
94. Sparrelid E., Ljungman P., Ekelof-Andstrom E., et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 19 (1997) 905-908
95. Meyers J.D. Fungal infections in bone marrow transplant patients. Semin Oncol 17 (1990) 10-13
96. Enright H., Haake R., Weisdorf D., et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 55 (1993) 1339-1346
97. Kadakia M.P., Rybka W.B., Stewart J.A., et al. Human herpesvirus 6: Infection and disease following autologous and allogeneic bone marrow transplantation. Blood 87 (1996) 5341-5354
98. Yoshikawa T. Human herpesvirus 6 infection in hematopoietic stem cell transplant patients. Br J Haematol 124 (2004) 421-432
99. Flomenberg P., Babbitt J., Drobyski W.R., et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 169 (1994) 775-781
100. Ochs L., Shu X.O., Miller J., et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 86 (1995) 3979-3986
101. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28 (1991) 250-259
102. Kawasaki H., Takayama J., and Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr 128 (1996) 353-356
103. Couriel D., Caldera H., Champlin R., et al. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101 (2004) 1936-1946
104. Schwartz J.M., Wolford J.L., Thornquist M.D., et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 96 (2001) 385-393
105. McDonald G.B., Hinds M.S., and Fisher L.D. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
106. Kumar S., DeLeve L.D., Kamath P.S., et al. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 78 (2003) 589-598